Compare Dow Inc (DOW) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Organon & Co. Common Stock — how do they compare? Dow Inc trades at $29.35 (market cap $20.59B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Dow Inc is far larger — about 5.7× Organon & Co. Common Stock's market cap, and Dow Inc pays the higher dividend (4.91%). Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 83 Days and Organon & Co. Common Stock for 0 Days on average.
| DOW | OGN | |
|---|---|---|
Market Cap | $20.59B | $3.62B |
Volume | 5,540,746 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $13.81 |
52-Week Low | $20.95 | $5.70 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $36.29B | $11.04B |
Dividend Yield | 4.91% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $29.19, up 3.81% on the day, with a bearish technical signal and neutral oscillators. The company reported negative net income of -$2.62B in 2025, with declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings have beaten expectations, but profitability metrics like ROE (-7.86%) and net margin (-3.13%) remain weak. Analyst consensus is a $33.80 price target with mixed ratings (30.56% Buy, 55.56% Hold).
The outlook is cautious due to persistent margin pressures and high debt levels, though the dividend payout and earnings beats offer some stability. Risks include cyclical demand weakness and rising leverage, but the stock trades below consensus target, suggesting potential upside if operational improvements materialize.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
